News · 19 November 2026

FDA approves a new drug for a hard-to-treat lung cancer

19 November 2026 · Health · US · Uplifting

FDA approves a new drug for a hard-to-treat lung cancer
Picture: MedPage Today · MedPage Today lead image · unknown

Neladalkib won accelerated approval for advanced ALK-positive lung cancer that grew back after earlier drugs. In a trial, it shrank tumors in 49% of patients who had taken only alectinib before. It is the seventh approved drug of its kind. The most common side effect was raised liver enzymes.

Where this came from. 2 outlets reported this. We read them, then wrote the sixty words above.

Also on 19 November 2026